Infectious Disease · Fungal Infections

Invasive Candidiasis

USMLE2PANCE
7

Bets

The facts most likely to be tested

1

Echinocandins (e.g., caspofungin) are the first-line empiric therapy for non-neutropenic patients with suspected invasive candidiasis.

Confidence:
2

Candida albicans remains the most common species, but Candida glabrata and Candida krusei are increasingly recognized for their intrinsic resistance to fluconazole.

Confidence:
3

Ophthalmoscopy is mandatory in all patients with candidemia to evaluate for chorioretinitis or endophthalmitis.

Confidence:
4

Central venous catheters are the primary source of infection and must be removed in most patients with documented candidemia.

Confidence:
5

Beta-D-glucan is a highly sensitive serum biomarker for invasive fungal infections, though it lacks specificity for Candida species.

Confidence:
6

Neutropenic patients with suspected invasive candidiasis require liposomal amphotericin B or an echinocandin as initial therapy.

Confidence:
7

Fluconazole is reserved for patients who are clinically stable and have documented susceptibility to azoles.

Confidence:

Vignette unlocked

A 62-year-old male in the ICU for 14 days following a bowel resection for perforated diverticulitis develops a persistent fever despite broad-spectrum antibiotic therapy. He has a central venous catheter in place for total parenteral nutrition. Blood cultures return positive for yeast. A dilated funduscopic exam reveals white, fluffy chorioretinal lesions.

What is the most appropriate initial pharmacologic treatment for this patient?

+Reveal answer

Echinocandin (e.g., caspofungin)

The patient has candidemia with evidence of ocular involvement; per IDSA guidelines, an echinocandin is the first-line empiric treatment for invasive candidiasis in non-neutropenic patients.

Mo

Depth

Full handout

High yield triage

Etiology / Epidemiology

Occurs in immunocompromised patients, ICU admissions, and those with central venous catheters or prolonged broad-spectrum antibiotics.

Clinical Manifestations

Presents as unexplained fever refractory to antibiotics; candidemia may lead to endophthalmitis or hepatosplenic involvement.

Diagnosis

Blood culture is the gold standard; (1,3)-beta-D-glucan assay is a highly sensitive adjunctive screening tool.

Treatment

Echinocandins (e.g., caspofungin) are the first-line therapy; avoid fluconazole in critically ill patients with prior azole exposure.

Prognosis

High mortality rate of 30-40%; requires ophthalmologic exam to rule out ocular seeding.

Full handout

Epidemiology & Etiology

Primarily affects patients with central venous catheters, total parenteral nutrition, or recent abdominal surgery. It is the most common invasive fungal infection in the ICU. Candida albicans remains the most frequent species, though non-albicans species like Candida glabrata are increasing.

Pertinent Anatomy

The infection typically originates from the gastrointestinal tract or intravascular devices. Hematogenous spread allows for seeding of the eyes, liver, spleen, and kidneys.

Pathophysiology

Disruption of the mucosal barrier or direct inoculation via catheters allows yeast to enter the bloodstream. The organism forms biofilms on prosthetic materials, making eradication difficult. The host immune response, specifically neutrophil function, is critical for containment.

Clinical Manifestations

Suspect in patients with persistent fever despite broad-spectrum antibacterial coverage. Look for candidal endophthalmitis, which presents as white, chorioretinal lesions on funduscopic exam. Red flags include septic shock, multiorgan failure, and skin nodules in neutropenic patients.

Diagnosis

Blood culture remains the gold standard, though sensitivity is only 50%. The (1,3)-beta-D-glucan test is a useful negative predictor due to high sensitivity. Ophthalmologic examination is mandatory for all patients with documented candidemia.

Treatment

Initiate Echinocandins (e.g., micafungin, caspofungin) empirically in hemodynamically unstable patients. Fluconazole is reserved for stable patients without prior azole exposure. Transition to oral fluconazole only after clinical stability and negative follow-up cultures.

Prognosis

Mortality is significantly higher in patients with delayed initiation of antifungal therapy. Ocular involvement can lead to permanent vision loss if not treated with systemic antifungals and potentially intravitreal injections.

Differential Diagnosis

Bacterial Sepsis: usually responds to initial empiric antibiotics

Aspergillosis: typically presents with pulmonary infiltrates/halo sign

Cryptococcosis: associated with meningitis and HIV/AIDS

Histoplasmosis: associated with bird/bat droppings and endemic geography

Endocarditis: characterized by new murmurs and vegetation on echocardiogram